Table 2 FOLFOX treatment, metastasis status and tumour recurrence sites

From: KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

Case

Primary site

Histopathological type

Pre-FOLFOX metastatic site

Synchronous/ metachronous

FOLFOX cycles

DFS (days)

Days from end of FOFLOX until recurrence

Post-FOLFOX recurrence site

1

Rectum

Mode

—

—

3

124

6

Liver

2

Colon

Mode

Liver

Synchronous

4

97

−16a

Liver

3

Colon

Mode

Liver

Synchronous

4

116

26

Liver

4

Rectum

Well

Local recurrence

Metachronous

4

469

363

Local recurrence

5

Rectum

Mode

—

—

5

827

603

Lung

6

Colon

Mode

—

—

5

350

244

Lymph node

7

Rectum

Mode

Liver

Synchronous

8

214

1

Lung

   

Lung

Synchronous

    

8

Rectum

Muc

—

—

8

538

318

Lung

9

Colon

Well

—

—

8

1077

903

Liver

10

Colon

Mode

Liver

Synchronous

8

344

120

Lung

   

Liver

Synchronous

   

Lung

   

Lung

Synchronous

    

11

Colon

Muc

Lung

Synchronous

9

721

401

Lung

12

Rectum

Well

Liver

Synchronous

9

109

−88a

Liver

13

Rectum

Mode

Liver

Metachronous

11

328

120

Liver

   

Lung

Metachronous

    

14

Rectum

Mode

Subcutaneous

Metachronous

12

519

156

Lung

15

Colon

Mode

—

—

12

388

176

Local recurrence

16

Rectum

Mode

Liver

Synchronous

12

466

210

Lung

17

Rectum

Well

Lung

Synchronous

12

556

264

Lung

18

Colon

Mode

Liver

Metachronous

12

531

231

Lung

        

Lung

19

Rectum

Mode

Liver

Synchronous

12

409

217

Lung

20

Rectum

Mode

—

—

12

455

243

Local recurrence

21

Rectum

Well

Liver

Metachronous

12

346

71

Lung

        

Lung

  1. Abbreviations: DFS=disease-free survival; mode=moderately differentiated adenocarcinoma; muc=mucinous adenocarcinoma; well=well-differentiated adenocarcinoma.
  2. aThe cases that FOLFOX therapies were administered after recurrence.